The plausible involvement of AGR2 and NPM3 in the regulation of PD-L1 expression might be of interest, as cancer cells are characterized by their ability to evade immune surveillance, during which they may either lose their antigenicity, orchestrate an immunosuppressive microenvironment or reduce their immunogenicity by expressing immunosuppressive molecules such as PD-L12. The gene discussed is AGR2; the disease is cancer.